Assessment of Pulmonary Functions and Peripheral Muscle Strength of COPD Patients in Different GOLD Stages

Pulmonary Functions and Peripheral Muscle Strength and Their Relationship With Disease Duration and Prognosis in Patients With Different COPD Stages

The purpose of this research was to examine the respiratory functions, respiratory muscle strength and peripheral muscle strength of patients with COPD in different groups and to evaluate their correlation with the duration and prognosis of the disease in COPD.

Study Overview

• Status: Completed
• Conditions: Copd
• Intervention / Treatment: Other: Assessment of COPD patients

Detailed Description

Chronic obstructive pulmonary disease (COPD) is a common disease characterized by airway obstruction against harmful particles and gases in the airway and lungs, and is progressive, treatable and preventable.

The severity of the disease in COPD is determined according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines (2). While determining the severity of airway obstruction with the patient's spirometric values in COPD; Combined COPD assessment is made with symptomatic evaluation, number of exacerbations and hospitalizations. Airway restriction is numerically (GOLD 1-4), symptom evaluation and exacerbation risk combined with letter grouping (Group A-D).

There is a loss of respiratory and peripheral muscle strength in COPD patients. A mixture of various local and systemic causes was responsible for respiratory muscle dysfunction in COPD. Immobility, systemic inflammation, hypoxia of the tissue, oxidative stress and increased apoptosis of the skeletal muscle have been identified as possible pathogenic factors for loss of peripheral muscle strength in COPD patients.

it was aimed to evaluate the respiratory functions, respiratory muscle strength and peripheral muscle strength of patients with different COPD groups clinically and to evaluate their correlation with the duration and prognosis of the disease.

• Study Type: Interventional
• Enrollment (Actual): 31
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Maltepe
    • Istanbul, Maltepe, Turkey, 34854
      • Marmara University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Being in COPD stable period and over the age of 40,
• The absence of abnormal laboratory findings,
• Not having a mental problem that prevents filling the questionnaires to be used in the study, - The absence of any other respiratory disease such as asthma,
• Giving the informed consent.

Exclusion Criteria:

• COPD exacerbation (hospitalization with acute exacerbation in the last 15 days),
• Presence of cognitive impairment,
• Pregnancy status,
• Ischemic heart disease,
• Kyphoscoliosis and advanced postural disorder,
• Orthopedic problems and amputation surgery,
• Emphysema, bullous lung disease,
• Presence of bronchiectasis,
• Previous thoracic surgery history,
• Presence of lung cancer,
• Advanced heart failure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Other: Assesment; Demographic information of all subjects (age, gender, educational status, occupation, body weight, height, body mass index), clinical (diagnosis period) and medical status, personal history and family history, COPD stage, COPD Assessment Test (CAT) score, emergency and hospital admissions numbers in the last 3 months, exacerbation and hospitalization numbers in the last one year were recorded. Respiratory and peripheral muscle strengths are evaluated. Also pulmonary functions test results obtained.

Other: Assessment of COPD patients; Assessments explained in the arm section were made as described in one session.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Respiratory Muscle Strength	It is a non-invasive test that indirectly demonstrates respiratory muscle strength with maximal inspiratory pressure (PImax) and maximal expiratory pressure (PEmax).Test were carried out according to American Thoracic Society (ATS) / European Respiratory Society (ERS) criteria.	10 minutes after obtaining socio-demographic information (It was done between the 10th and 20th minutes of the assessment).
Peripheral Muscle Strength Assessment-Upper extremity	Upper extremity: For grip strength test a manual hydraulic dynamometer was used according to the recommendations of the American Association of Hand Therapists (AETD). The patients were measured in sitting position, shoulder adduction at 90 °, elbow flexion, forearm in pronosupination, neutral and wrist joints in neutral position. Three consecutive measurements were obtained by giving 60-second rest breaks between measurements. The result obtained from the average of three measurements was recorded.	25 minutes after obtaining socio-demographic information. After the respiratory muscle strength evaluation, the patients were rested for 5 minutes (It was done between the 25th and 35th minutes of the assessment).
Peripheral Muscle Strength Assessment-Lower extremity	M. Quadriceps femoris strength was evaluated for knee extension. M. Hamstring strength was evaluated for knee flexion. The test was applied with the "make test" technique that requires isometric contraction. Participant was asked to maintain maximum isometric contraction for 5 seconds, and the average of 3 consecutive maximum contraction measurements performed at 30-second intervals was recorded.	40 minutes after obtaining socio-demographic information. After Upper extremity muscle strength evaluation patients were rested for five minutes (It was done between the 40th and 55th minutes of the assessment)
Pulmonary Function Test (PFT) results	The PFT results of patients' performed during their routine controls taken into consideration. The percentages of the predicted values (percent) for forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC, mid-expiratory flow rate (MEF25-75) and peak expiratory flow (PEF) were used for statistical analysis.	55 minutes after obtaining socio-demographic information.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of the disease	Diagnosis year of the patient were recorded.	After the permission of patients, in the first 10 minutes of assessment while obtaining socio-demographic information of patients.
Exacerbation numbers in last one year	Exacerbation numbers in last one year of the patients were recorded.	After the permission of patients, in the first 10 minutes of assessment while obtaining socio-demographic information of patients.
Hospitalization numbers in last one year	Hospitalization numbers in last one year of the patients were recorded.	After the permission of patients, in the first 10 minutes of assessment while obtaining socio-demographic information of patients.

Collaborators and Investigators

• Sponsor: Marmara University
• Investigators: Principal Investigator: Begum Unlu, PT, MSc, Marmara University

Study record dates

Study Major Dates

• Study Start (Actual): February 8, 2019
• Primary Completion (Actual): May 23, 2019
• Study Completion (Actual): June 19, 2019

Study Registration Dates

• First Submitted: March 9, 2021
• First Submitted That Met QC Criteria: March 16, 2021
• First Posted (Actual): March 18, 2021

Study Record Updates

• Last Update Posted (Actual): March 18, 2021
• Last Update Submitted That Met QC Criteria: March 16, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Keywords: COPD; Respiratory muscle strength; Pulmonary functions; Peripheral muscle strength
• Other Study ID Numbers: SAG-C-YLP-131217-0652

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No